Bio-Techne (TECH) risk factors, FY2025 10-K

Bio-Techne's FY2025 10-K, filed Aug 22, 2025, lists 24 risk factors in 3 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
243 groups
Section length
10k wordsItem 1A

Bio-Techne's biggest risks in the FY2025 10-K

  • International sales drive 44% of revenue, exposing Bio-Techne to global trade and geopolitical tensions.
  • Acquisition strategy and integration risks are critical for growth in Protein Sciences.
  • Heavy reliance on internal manufacturing and third-party cold-chain delivery creates operational vulnerabilities.

The risks most specific to Bio-Techne

  • International political, compliance and business factors, including the military conflict in Ukraine, Israel’s conflict in Gaza, and trade tensions between the U.S. and China, can negatively impact our operations and financial results

    Approximately 44% of sales revenue comes from outside the U.S., exposing operations to international conflicts, trade tensions, and regulatory changes.

  • The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results

    Protein Sciences segment products depend on research funding and spending by pharmaceutical companies and academic institutions.

  • Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price

    Growth relies on the ability to continuously acquire and integrate other businesses and assets at appropriate prices.

  • Strategic and Operational Risks

    The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites

    Internal quality control, packaging, and distribution operations support the majority of sales and must comply with FDA regulations.

  • Strategic and Operational Risks

    Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us

    Significant operations in California face climate change risks such as serious drought and increased wildfire hazards.

  • Strategic and Operational Risks

    Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability

    Reagent products require specific cold temperatures and rely heavily on third-party express shippers like FedEx and DHL.

  • Financial and Tax Risks

    We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy

    The company has drawn $313 million under a $1 billion revolving credit facility, exposing it to variable interest rate burdens.

All 24 risk factors

Headings as the filing states them, in filing order.

Other

  1. 01Economic and Industry Risks
  2. 02Conditions in the global economy, the particular markets we serve and the financial markets, whether brought about by material global crises or other factors, may adversely affect our business and financial results
  3. 03International political, compliance and business factors, including the military conflict in Ukraine, Israel’s conflict in Gaza, and trade tensions between the U.S. and China, can negatively impact our operations and financial results
  4. 04The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results
  5. 05Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price
  6. 06Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results
  7. 07We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price

Strategic and Operational Risks

  1. 08Our success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions
  2. 09Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers’ needs. Our growth can also be negatively impacted if our customers do not grow as anticipated
  3. 10We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive
  4. 11A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements
  5. 12If we suffer loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed
  6. 13The manufacture of many of our products is a complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial results could suffer
  7. 14The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites
  8. 15Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us
  9. 16Defects, unanticipated use of, or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results
  10. 17Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability
  11. 18We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights
  12. 19We may be involved in disputes to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business

Financial and Tax Risks

  1. 20We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy
  2. 21Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws)
  3. 22Dividends on our common stock could be reduced or eliminated in the future

Legal, Regulatory, Compliance and Reputational Risks

  1. 23Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results
  2. 24Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners

Other Bio-Techne 10-Ks

  • FY2026 10-K risk factors
    29 risks5 new3 reworded

    The proposed Merck KGaA acquisition adds deal-completion, regulatory, shareholder-vote and $73-per-share transaction risks.

    Filed Aug 24, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.